BMS Q&A: Hunting For Biomarkers To Improve Treatment Of Autoimmune Diseases
Bristol-Myers R&D leaders Brian Gavin and Sean Connolly offered insight into the company's immunology focus for autoimmune diseases, which increasingly is driven by a search for biomarkers that point to the best use of the big pharma's drugs.
You may also be interested in...
Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Janux reported early clinical trial data for its lead asset JANX007 that may show differentiated efficacy in the crowded PSMA space and for an EGFR agent with lung and kidney tumor shrinkage.